Abstract
Introduction
Targeted radionuclide therapy relies on the administration of radiolabeled compounds to irradiate tumors [1] . Iodine-131 has been used since seven decades to prevent recurrence of thyroid cancer after surgery and to treat distant metastases [2] [3] [4] . In the past years, several other tumor-targeting radiopharmaceuticals, labeled with iodine-131, yttrium-90, or lutetium-177, have successfully entered
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International Publisher into clinical practice. Examples include 131 I-MIBG for neural crest tumors, anti-CD20 antibodies (e.g. 90 Y-ibritumomab tiuxetan) for lymphomas [5] , the somatostatin analogs 90 Y-DOTATOC and 177 Lu-DOTATATE for neuroendocrine tumors [6] and more recently 177 Lu-labelled PSMA ligands for metastatic prostate cancer [7] . Notably, an ever-increasing number of preclinical studies and clinical trials aim at using radionuclide therapy to treat minimal residual disease: i.e. as adjuvant therapy or for consolidation after remission [8] [9] [10] [11] [12] [13] .
Many of the novel radiopharmaceuticals for targeted therapy have been armed with lutetium-177 [6] [7] [8] [9] . 177 Lu can be stably chelated to various peptides and antibodies [14] . Compared to the high-energy electrons of 90 Y, the medium-energy β -emission of 177 Lu allows for a more effective irradiation of small tumors and is associated with a reduced non-specific toxicity [15] [16] [17] [18] . Both characteristics are important in the perspective of targeting minimal residual disease. Moreover, 177 Lu emits γ photons which enable post-therapy imaging.
Three other promising medium-energy β -emitters are: copper-67 [19, 20] , scandium-47 [21, 22] and terbium-161 [23] [24] [25] . Their half-lives are suitable for targeted radionuclide therapy with peptides and antibodies ( Table 1 ). The half-life of 161 Tb (6.91 d) is similar to that of 177 Lu (6.65 d). The half-lives of 67 Cu and 47 Sc are shorter (respectively 2.58 d and 3.35 d) and thus they might be used to label molecules that exhibit a more rapid washout from tumor tissues. Just like 177 Lu, 161 Tb is a radiolanthanide that can be stably linked to various molecules using for example DOTA as chelator [24, 25] . Chelators that are suitable for stable coordination of copper and scandium are also available [14] . All three radionuclides are amenable to imaging thanks to some gamma photon emissions (Table 1) . Photons from 67 Cu and 47 Sc (184.6 keV and 159.4 keV, respectively) are better suited to post-therapy imaging with gamma cameras than the photons emitted by 161 Tb (whose energy of 74.6 keV is similar to that emitted by the myocardial imaging agent 201 Tl). On the other hand, the lower proportion of photon emission of 161 Tb (~15% of the total emitted energy, compared to ~40% for 67 Cu or 47 Sc) minimizes total body dose and allows for treatment on an outpatient basis.
One major advantage of these radionuclides over 177 Lu is the theranostic potential, i.e. the availability of β + ( 64 Cu, 43 Sc, 44 Sc, 152 Tb) or γ-emitting ( 155 Tb) radioisotopes that enable PET or SPECT pre-therapy imaging and dosimetry [26] [27] [28] [29] [30] . Table 2 summarizes the physical properties of these diagnostic radionuclides. The biodistribution of the molecule labeled with the diagnostic radionuclide is expected to faithfully match that of the therapeutic molecule.
The aim of this study was to compare the effectiveness of 67 Cu, 47 Sc and 161 Tb at irradiating small tumors. Using the Monte Carlo code CELLDOSE [31, 32] , we assessed the dose deposits from these radionuclides in spheres of various sizes, simulating micrometastases and single tumor cells.
Methods
The absorbed dose in each sphere was assessed with Monte Carlo simulations by taking into account all electron emissions: β-spectra, conversion electrons (CE) and Auger electrons (including Coster-Kronig electrons). Emission data were obtained from the International Commission on Radiological Protection (ICRP) publication ICRP-107 [30] . Photons were neglected. For all simulations, the distribution of radioactivity within spheres was assumed to be homogeneous. This was achieved by random Monte Carlo sampling throughout the sphere volume using a high number of simulations (≥ 1,000,000 per sphere). Decay characteristics of 67 Cu, 47 Sc and 161 Tb are reported in Table 1 . The spectra of electron emissions are shown in Figure 1 . Event-by-event electron track simulations in CELLDOSE are based on the cross sections of the interactions between the electron and the water molecule, and take into account ionizations, excitations and elastic scattering processes [31] [32] [33] . The slowing-down histories for primary and secondary electrons are described until the energy falls to 7.4 eV (electron excitation threshold of the water molecule) [33] . The residual energy is considered to be absorbed locally.
The doses from a single radioactive decay (S-values) for 67 Cu and 47 Sc were assessed in spheres of water density and compared with those previously calculated for 161 Tb in the same spheres [18] . The diameter of the spheres ranged from 5 mm to 10 µm, thus simulating micrometastases of various sizes and single tumor cells. The relative contribution from the different electron emissions (β -particles, CE, Auger electrons) was also assessed as previously described with 131 I [31] .
In addition to S-values, we calculated the absorbed dose resulting from a uniform concentration of events (1 decay Table 3 . Results agreed (differences <10%) with those reported by Bardiès for 67 Cu and 47 Sc in spheres >20 µm using analytic methods based on scaled dose point kernel [34] . Bardiès and colleagues did not report on smaller spheres and did not study Terbium-161. The relative contributions of β -particles, CE and Auger electrons are also reported in Table 3 . In the case of 47 Sc, almost all the absorbed dose was due to β -emission (>99% for all spheres). β -emission was also the main contributor to the doses delivered by 67 Cu, with only modest contribution from CE and Auger electrons (10.1 to 29.3%). By contrast, 161 Tb displayed a significant contribution from CE and Auger electrons. The combined contribution from 161 Tb CE and Auger electrons to the total absorbed dose was 25.9% in the 5-mm sphere and reached 88.3% in the cell-sized 10-µm sphere (Table 3) .
Electron dose deposits after normalization
When 1 MeV per µm 3 was released, the absorbed dose in the 5-mm sphere was similar for the three radionuclides (146 to 149 Gy). The absorbed dose progressively decreased when the sphere size decreased, but the dose reduction was more abrupt for 67 Cu and 47 Sc than for 161 Tb (Fig. 2) . 161 Tb was clearly superior to the other radionuclides for spheres with less than 1mm diameter. For example, in a 100-µm micrometastasis the absorbed dose was 24.1 Gy with 67 Cu, 14.8 Gy with 47 Sc and 44.5 Gy with 161 Tb (Table 4 ). The largest dose difference was found in cell-sized spheres: in the 10-µm sphere, the doses delivered by 67 Cu, 47 Sc and 161 Tb were 3.42 Gy, 1.74 Gy and 14.1 Gy, respectively (Table 4) . 
Electron energy deposit around a point source
The energy deposited by 161 Tb (per MeV released) was considerably higher than that deposited by the other radionuclides up to 30 µm around the point source (Fig. 3) . This suggests that 161 Tb would deliver a higher dose not only to the targeted cell, but also to its immediate neighbors. Beyond this distance, the differences in energy deposits leveled off: the radius within which 50% of the energy is deposited (R50) was 0.17 mm for 67 Cu, 0.25 mm for 47 Sc and 0.15 mm for 161 Tb. The radius within which 90% of the emitted energy is deposited (R90) was 0.57 mm for 67 Cu, 0.72 mm for 47 Sc and 0.63 mm for 161 Tb.
Discussion
In many cancers, the prognosis is linked to metastatic relapse, which may occur years after primary surgery [35] [36] [37] . Targeted radionuclide therapy may play a major role to treat occult micrometastases in high-risk patients or to eradicate minimal residual disease [2, [8] [9] [10] [11] [12] [13] . Several preclinical and clinical studies suggest that radionuclide therapy is more effective when administered at an early stage of the disease [4, 6, 38, 39] , probably because the distribution of the radiopharmaceutical in tumors is still relatively homogeneous. However, radionuclides differ in their ability to irradiate micrometastases [16] . In this study we assessed the relative effectiveness of three promising medium-energy β-emitters, i.e. 67 Cu, 47 Sc and 161 Tb.
Since the electron energy per decay of these three radionuclides differs, we assumed that 1 MeV was released per µm 3 . If totally absorbed, this energy would always yield a dose of 160 Gy. Absorbed doses of this magnitude were measured in macrometastases of neuroendocrine tumors in patients who responded to 177 Lu-DOTATATE therapy [40] . Smaller and more homogeneous tumors are expected to respond to lower doses.
Our simulations showed that, for the three radionuclides, the doses delivered to a 5-mm metastasis (146 to 149 Gy) were close to the dose that would result from total absorption. The doses decreased with sphere size, thus underscoring the fact that micrometastases are more difficult to irradiate effectively. The dose delivered by 161 Tb was however consistently higher than that delivered by the other radionuclides (Fig. 2) . For example, in a 100-µm micrometastasis, the absorbed dose was 44.5 Gy for 161 Tb, 24.1 Gy for 67 Cu and 14.8 Gy for 47 Sc (Table 4) . The largest differences were found in the smallest spheres: in a cell-sized sphere of 10 µm diameter, the dose delivered by 161 Tb was 14.1 Gy, compared to 3.42 Gy and 1.74 Gy for 67 Cu and 47 Sc. Thus, relatively to the almost pure β -emission of 47 Sc, the doses delivered by 161 Tb were ~3 times higher in a 100-µm micrometastasis and ~8 times higher in a 10-µm single cell (Table 4 ). In a previous work, we showed that the dose delivered by 161 Tb to small metastases was also higher than that delivered by 177 Lu [18] . In Table 4 , the absorbed doses from 67 Cu, 47 Sc and 161 Tb (for 1 MeV released per µm 3 ) are compared to those from 177 Lu, used as a reference.
Our Monte Carlo study provides a mechanistic framework that explains some recent preclinical findings on tumor-control efficacy [24, 25] . Anti-L1CAM antibody labeled with 161 Tb inhibited the growth of subcutaneous xenografts of ovarian cancer more effectively than the same antibody labeled with 177 Lu and injected at a comparable activity (corresponding to 50% of the maximum tolerated dose) [25] . In a cell culture study, the radioactivity concentration of folate conjugates required to achieve the half-maximal inhibition of KB cells (human cervical carcinoma) was 4.5 fold lower with the 161 Tb-labeled conjugate than with the 177 Lu-labeled conjugate [24] . This difference was smaller (×1.7) for IGROV-1 cells (human ovarian carcinoma), which might be explained by the lower internalization rate of folate conjugates into these cells [24] .
The higher efficacy of 161 Tb compared to 47 Sc and 67 Cu is mainly due to the larger amount of Auger and low-energy conversion electrons (Fig. 1) , whose doses are deposited over relatively short distances (Fig. 4) . Indeed, CE and Auger electrons accounted for 71% of the radiation dose deposited by 161 Tb in a 100-µm metastasis and 88% of the dose deposited in a 10-µm cell (Table 3 ). This contrasts with 47 Sc data, where >99% of the absorbed energy was due to β -particles for all spheres. The interpretation of experimental results may be further refined by considering the linear energy transfer (LET) of emitted electrons. Not only emission spectra from 161 Tb are rich in Auger electrons, but also the majority of conversion electrons of 161 Tb have low energy (< 50 keV) and thus high LET (Table 5 ). [33] . The highest LET value is for electrons whose energy is close to 0.15 keV.
Knowledge of the biodistribution of the radiopharmaceutical at the cellular and subcellular level is of paramount importance to rationally choose the most appropriate radionuclide. Radionuclides can be imaged and quantified with techniques such as autoradiography or secondary ion mass microscopy [41] . This distribution may be used as input to derive the dose to tumor cells [32] . The energy deposited by 161 Tb (per MeV released) is higher than that deposited by the other radionuclides up to 30 µm around a point source (Fig. 3) . Thus, 161 Tb would likely deliver a higher dose, not only to the targeted cell, but also to its immediate neighbors. Moreover, the short tracks of energy deposit of Auger electrons and some low energy conversion electrons (Fig. 4) suggest that a putative 161 Tb-labeled radiopharmaceutical would be even more effective if transported into the cell and internalized into the nucleus [42] . The impact of Auger electrons on other targets such as the cell membrane also deserves investigation [43] . Our future work will compare the dose distribution of 161 Tb to that of other β-, Auger-or α-emitting radionuclides [44] for various cellular distributions. Also, since only limited preclinical work on 161 Tb has been done so far [24, 25] , additional studies should be carried out to establish whether 161 Tb is a good candidate for clinical use. Hopefully, preclinical data [24, 25] , and the theoretical framework provided by our own calculations, will encourage the development of new radiopharmaceuticals labelled with 161 Tb.
Finally, the choice of radionuclides for radiopharmaceutical therapy may be driven by logistic issues. Producing 67 Cu as no-carrier-added in amounts suitable for large clinical use has been difficult [19, 20] . The optimal technique to produce 47 Sc is still debated [21, 22] . Preliminary data suggest that 161 Tb can be produced in large amounts as no-carrier-added, using for example a gadolinium-160 target ( 160 Gd(n,γ) 161 Tb), and with good radionuclide purity ( 160 Tb to 161 Tb activity ratio <0.0001) [45] . The cost for large-scale production is estimated to be comparable to that of no-carrier-added 177 Lu [45] .
Conclusion
Radiopharmaceutical therapy can effectively target isolated tumor cells and occult micrometastases, provided that the optimal radionuclide is used. Our investigations on three theranostic radionuclides suggest that 161 Tb might be a better choice than 67 Cu or 47 Sc. The promising characteristics of this radionuclide justify further preclinical investigations and, hopefully, clinical trials.
